Return to search

Targanta Sets IPO Terms

Targanta Therapeutics Inc., a Cambridge, Mass.-based developer of antibacterial agents, has set its IPO terms to 5.75 million common shares being offered at between $12 and $14 per share. It would have an initial market cap of approximately $293.5 million, were it to price at the high end of its range. Shareholders include Brookside Capital Partners (15.2% pre-IPO position), InterMune Inc. (15.2%), Skyline Ventures (13.2%), VenGrowth (11.8%), OrbiMed Advisors (11.1%), T2C2 (7.3%), Canadian Medical Discoveries Fund (7.1%), Seaflower Ventures (7%) and Radius Ventures (6.1%). www.targanta.com